Routes to UV Activated Fouling Reversal and Molecular Weight Cutoff Control in Tethered Micelle Ultrafiltration Membrane Assemblies

1160026贝利该NSF奖由化学、生物工程、环境和运输系统(CBET)分部的化学和生物分离计划以及化学部的高分子、超分子和纳米化学(MSN)计划颁发，支持Travis S.Bailey教授开发一种新的与生物分离相关的新型超滤膜，这些超滤膜在一系列行业中普遍存在，特别是涉及抗体和蛋白质药物纯化的制药过程。在路透社2011年4月发表的一篇最近的文章中，预计早在2014年，世界上最畅销的10种S药物中，有8种将是基于抗体的生物制品。由于当前膜技术(如蛋白质A型柱)成本较高，过度污染导致膜寿命有限，以及难以整合到大规模纯化工艺流程中，涉及这些生物制剂生产的分离仍然占生产成本的很大一部分。为了应对这些基本挑战，本工作探索了一种基于光活性系留胶束网络的超滤膜制备的新方法，该网络由纳米结构嵌段共聚物组装而成。拟议研究的主要目标是开发和验证这种新型超滤膜的潜力，以提供(1)高通量，(2)窄而均匀的孔径分布，(3)用户能够调节的分子量截止范围，以及(4)内置的抗污染和反转能力。与更高效率的超滤过程相关的累积能量(因此成本)节省将在全球范围内产生影响，从而显著降低与抗体和其他基于蛋白质的药物推向市场相关的提纯处理成本。改进的污垢阻力和有效的反转策略将进一步扩大超滤是可行分离解决方案的系统范围。

1160026BaileyThis NSF award by the Chemical and Biological Separations program of the Chemical, Bionengineering, Environmental, and Transport Systems (CBET) Division and the Macromolecular, Supramolecular and Nanochemistry (MSN) Program of the Chemistry Division supports work by Professor Travis S. Bailey to develop new a new class of ultrafiltration membranes relevant to biological separations prevalent across a range of industries, particularly pharmaceutical processes involving antibody and protein based drug purification. In a recent article by Reuters published in April 2011, it was projected that as early as 2014, 8 of the 10 world?s top selling drugs will be antibody based biologics. Separations involving the manufacture of these biologics continue to represent a major fraction of the production cost, due to high costs of current membrane technologies (e.g. Protein A type columns), limited membrane lifetimes due to excessive fouling, and difficult integration into large scale purification process flows. In response to these fundamental challenges, this work explores a new approach to ultrafiltration membrane fabrication based on photoactive tethered micelle networks, assembled from nanostructured block copolymer assemblies. The principal objectives of the proposed research are to develop and validate the potential of this new class of ultrafiltration membranes to provide (1) high flux, (2) narrow and uniform pore size distributions, (3) user-enabled tuning of the molecular weight cutoff regimes and (4) built in fouling resistance and reversal capabilities. Cumulative energy (and therefore cost) savings associated with higher efficiency ultrafiltration processes would have worldwide impact, dramatically reducing purification processing costs associated with antibody and other protein based drugs being brought to market. Improved fouling resistance and effective reversal strategies would additionally extend the range of systems for which ultrafiltration is a viable separations solution.